![]() Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. | ![]() Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| ||
Founding Date | Founding Date 2007 | Founding Date 2006 | Founding Date 2000 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US |
Employees | Employees 17 | Employees 31019% decrease | Employees 999 |
Valuation ($) | Valuation ($) 11.8 m | Valuation ($) 1.5 m | Valuation ($) 648.3 m |
Financial | |||
Revenue (est.) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €53.8m (FY, 2023) |
Cost of goods | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods €64.3m (FY, 2023) |
Gross profit | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) |
Net income | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income (€260.2m) (FY, 2023) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.1b |
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyCureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View company